Key facts
- The FDA has, for the first time, authorized a nicotine pouch to be marketed as lower-risk than cigarettes — 20 ZYN products, on July 2, 2026.
- The exact claim it approved: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
- It applies only to adults who switch completely from smoking — and lower-risk isn’t risk-free: the nicotine is still addictive.
For the first time, the FDA has said a nicotine pouch can be legally marketed as lower-risk than smoking. On July 2 the agency granted Swedish Match — the Philip Morris-owned maker of ZYN — “modified risk” orders for 20 of its pouches, clearing them to carry a claim most tobacco products never get near.
The FDA chose the wording precisely: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” It’s aimed at adults who switch completely off cigarettes — not at people using both.
It’s worth being clear on what actually changed, because it’s bigger than it sounds. ZYN has been legally on sale in the US since January 2025, when the FDA authorized it for market. July 2 is a different, rarer thing: permission to advertise a reduced-risk claim. The FDA has issued that kind of order only a handful of times ever, because the bar is high — a company has to show the claim is scientifically accurate, that ordinary people read it correctly, and that allowing it benefits public health overall. The agency decided Swedish Match cleared all three for these 20 products (10 flavors, in 3mg and 6mg).
What it means if you smoke. In plain terms, the US regulator is now formally on record that switching from cigarettes to these pouches lowers your risk of several of the diseases that make smoking so deadly. That’s a real harm-reduction milestone. But the FDA was just as clear about the fine print, and so are we: these aren’t risk-free, the nicotine in them is addictive, and if you don’t use tobacco at all, the healthiest move is to keep it that way. “Lower risk than a cigarette” is a low bar — it doesn’t mean low risk. If you’re weighing strengths, our guides to nicotine strengths and how much nicotine is in a cigarette put the numbers in context; if you’d rather take nicotine out of the equation entirely, there are nicotine-free options too.
The pushback is all about kids. The Campaign for Tobacco-Free Kids opposed the claim, and the timing sharpened the fight. The FDA’s own 2025 National Youth Tobacco Survey, out June 23, found roughly 460,000 US middle and high schoolers — about 1.7% — using nicotine pouches: more than nine in ten of them chose a flavored version, mint was the favorite, and ZYN was the brand named by 69% of young users. Mint is among the flavors covered by the new orders, which is exactly what critics point to.
The FDA did build in a leash. The orders run five years, Swedish Match has to carry out postmarket surveillance — including tracking whether more teenagers pick the products up — and the agency says it can withdraw the authorization if the picture sours, a youth spike being the obvious trigger. So this story isn’t finished on day one. The next couple of years of data decide whether it reads as a win for smokers trying to quit, or an on-ramp for kids — and that’s the number worth watching.
